- Conditions
- Pancreas Cancer, Pancreas Adenocarcinoma
- Interventions
- Capecitabine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Molybdenum Cofactor Deficiency, Type A
- Interventions
- ORGN001 (formerly ALXN1101)
- Drug
- Lead sponsor
- Origin Biosciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Organ Donation
- Interventions
- Control ending - Uplifting, Negative Consequences Ending, Unresolved Ending
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Molybdenum Cofactor Deficiency
- Interventions
- Not listed
- Lead sponsor
- Origin Biosciences
- Industry
- Eligibility
- 1 Day and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Milwaukee, Wisconsin
- Conditions
- Molybdenum Cofactor Deficiency, Isolated Sulfite Oxidase Deficiency
- Interventions
- Not listed
- Lead sponsor
- Origin Biosciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia • Woodinville, Washington
- Conditions
- Von Willebrand Diseases
- Interventions
- Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Interventions
- 5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin, CoFactor (ANX-510)
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 46
- States / cities
- Florence, Alabama • Anaheim, California • Apple Valley, California + 41 more
- Conditions
- NAFLD
- Interventions
- homocysteine (Hcy) lowering supplements
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
- Interventions
- ALXN1101, Placebo
- Drug
- Lead sponsor
- Origin Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Maternal Obesity
- Interventions
- Pyrroloquinoline quinone (PQQ), Placebo with soybean oil
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Molybdenum Cofactor Deficiency, Type A
- Interventions
- ORGN001 (formerly ALXN1101)
- Drug
- Lead sponsor
- Origin Biosciences
- Industry
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- Myelodysplastic Syndromes
- Interventions
- High-dose ascorbate, Azacitidine
- Drug
- Lead sponsor
- Prajwal Dhakal
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
- Interventions
- KPT-9274
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Adults
- Interventions
- CoFactor, Leucovorin
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- RP-3500, Olaparib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
- Interventions
- coenzyme Q10, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- CoFactor and 5FU
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • San Diego, California + 2 more